BioCentury | Mar 25, 2019
Distillery Therapeutics

IL-17RD or inhibition of ZEB1 to sensitize lung cancer to MEK inhibition

...Lung cancer Patient sample, cell culture and mouse studies suggest IL-17RD or blocking ZEB1 via miR-200...
...a mouse model of lung cancer treated with selumetinib, co-treatment with a synthetic mimic of miR-200...
...and solid tumors. TARGET/MARKER/PATHWAY: Interleukin-17 receptor D (IL-17RD); zinc finger E-box binding homeobox 1 (ZEB1); microRNA-200 (miR-200)...
BioCentury | Oct 27, 2016
Distillery Therapeutics

Biomarkers

TECHNOLOGY: Gene profiling A panel of five microRNAs could be used for the differential diagnosis of subtypes of aggressive prostate cancer and to predict the risk of disease progression. Exon sequencing of serum samples from...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: MicroRNA-9 (miR-9); miR-200c

Cancer INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting miR-9 or promoting miR-200c expression could help treat triple-negative breast cancer (TNBC). In patient samples, high tumor miR-9 levels correlated with poor metastasis-free survival...
BioCentury | Jun 30, 2016
Distillery Techniques

Techniques: A 15-microRNA (miRNA) signature to predict survival in patients with colon, pancreatic and stomach cancers

...let-7c), microRNA-99a (miR-99a) , miR-100 , miR-125b , miR-141 , miR-192 , miR-194 , miR-200...
BioCentury | Sep 10, 2015
Distillery Therapeutics

Therapeutics: MicroRNA-200 (miR-200)

...inhibiting miR-200 could help treat DNA damage-induced complications of Type I diabetes. Serum levels of miR-200...
...complications. In patient-derived fibroblasts and iPS cells from the patients with severe complications, siRNA against miR-200...
...Next steps could include design and testing of miR-200 inhibitors in models of diabetes. TARGET/MARKER/PATHWAY: MicroRNA-200 (miR-200)...
BioCentury | Jul 10, 2014
Distillery Techniques

Technology: Markers

...status Publication and contact information Markers Low ERBB receptor feedback inhibitor 1 (ERRFI1; MIG6) to microRNA-200 (miR-200)...
...receptor (EGFR) to EGFR inhibition In vitro and mouse studies suggest a low MIG6 to miR-200...
...with human wild-type EGFR lung and pancreatic tumor xenografts, a high ratio of MIG6 to miR-200...
BioCentury | Dec 12, 2013
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Transcription activator-like effector nucleases (TALENs) selectively targeting individual microRNAs A library of TALEN-mediated miRNA knockouts could help study miRNA function. A...
BioCentury | Jul 1, 2010
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer MicroRNA-200 (miR-200); Fas receptor (CD95); protein...
...CD95); protein tyrosine phosphatase non-receptor type 13 (PTPN13; FAP-1) In vitro studies suggest that boosting miR-200...
...a regulator of CD95-mediated apoptosis. Stable expression of miR-200 reduced FAP-1 abundance, whereas knockdown of miR-200...
BioCentury | Sep 24, 2009
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer MicroRNA-200 (miRNA-200) A study in...
BioCentury | Aug 27, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact nformation Cancer Breast cancer BMI1 polycomb ring finger oncogene (BMI1); microRNA-200c (miRNA-200c) Studies in mice and in cell culture suggest that increasing miRNA-200c expression in breast tissue...
Items per page:
1 - 10 of 11